Rosuvastatin for the prevention of aminoglycoside-induced kidney toxicity in children with cystic fibrosis
Cystic fibrosis causes thick mucus to build up in the lungs, which often leads to chest infections. A common treatment for these infections is an antibiotic called tobramycin, given directly into a vein. While tobramycin is very effective, it can sometimes cause kidney problems. Researchers want to see if adding a daily tablet called rosuvastatin can protect the kidneys while young people receive tobramycin. This trial is open to children and teenagers aged 10 to 18 with cystic fibrosis who need intravenous tobramycin. Half of the participants will take a rosuvastatin tablet each day during their antibiotic course, while the other half will have standard treatment without the extra tablet. The study lasts about six weeks, involves five hospital visits, and includes urine and blood tests to monitor kidney health closely.
At a glance
What is this study about?
Cystic fibrosis is an inherited condition that causes thick, sticky mucus to collect in the lungs and digestive system. Because of this mucus, children and teenagers with cystic fibrosis often develop chest infections that need strong treatments. A medicine called tobramycin is frequently used to clear these infections. It is given straight into a vein through a drip or cannula, which doctors call intravenous (IV) treatment.
While tobramycin is very good at fighting chest infections, it can sometimes cause temporary or permanent damage to the kidneys. Doctors want to find ways to make this essential treatment safer. Earlier research suggests that a widely used medicine called rosuvastatin might shield kidney cells from the harmful effects of tobramycin.
This clinical trial aims to find out whether taking a daily rosuvastatin tablet alongside IV tobramycin really does protect the kidneys. By comparing patients who take rosuvastatin with those who receive standard treatment alone, researchers hope to improve future care and help keep kidneys healthy for young people with cystic fibrosis.
Key takeaways
- Tests whether rosuvastatin tablets protect kidneys from damage caused by the antibiotic tobramycin.
- Open to children and teenagers aged 10 to 18 with cystic fibrosis needing IV tobramycin.
- Participants take a daily tablet or receive standard care for about two weeks.
- Involves five hospital visits, daily urine samples, and extra blood tests over six weeks.
- Taking part is voluntary and does not affect regular NHS care.
Who may be eligible?
This study is open to young people aged 10 to 18 who have cystic fibrosis and are planned to have a course of IV tobramycin. Participants must be able to swallow tablets and be willing to attend the study visits and provide blood and urine samples.
Children cannot take part if they already take a statin, have had an allergic reaction to statins in the past, or have existing kidney, liver, or muscle conditions. Certain medications cannot be taken alongside rosuvastatin, including specific antibiotics, antifungals, and the contraceptive pill.
In addition, patients who are pregnant or breastfeeding cannot join, and girls of childbearing age must take a pregnancy test and use reliable barrier contraception during the study. Because of differences in how the body processes statins, young people of Asian family background are also not able to take part in this particular trial.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you or your child aged between 10 and 18 years?
- Do you have a confirmed diagnosis of cystic fibrosis?
- Are you scheduled to start a course of IV tobramycin?
- Are you able and willing to swallow tablets?
- Are you free from existing serious kidney, liver, or muscle conditions?
What does participation involve?
Taking part in this study lasts for about six weeks in total. A computer randomly assigns each participant to one of two groups. One group takes a daily rosuvastatin tablet during their IV tobramycin treatment (usually around 14 days), while the other group receives their usual tobramycin care without the tablet.
Participants will have five study visits. The team aims to schedule these visits alongside routine hospital appointments, but taking part usually means about two extra visits and a few additional blood tests. Daily urine samples will also be collected during the antibiotic course. A final follow-up check takes place four weeks after finishing tobramycin to see how the kidneys are doing.
Potential risks and benefits
Locations (1)
- Alder Hey HospitalApproximateLiverpool, England
Common questions
What is rosuvastatin?
Rosuvastatin is a medicine from a group called statins. It is usually used to lower cholesterol, but research suggests it may also help shield kidneys from injury.
Will my child definitely receive rosuvastatin?
No. A computer randomly decides who gets the tablet and who does not. Each participant has a 50% chance of being in either group.
Can my child keep taking rosuvastatin after the study ends?
No. The medicine stops when the course of tobramycin finishes, even if it appeared to be helpful.
Does taking part mean more blood tests?
Yes. While the team tries to time tests with routine care, participants will typically need about two extra blood tests and visits.
What happens if we decide to leave the trial early?
You can leave the trial at any point without giving a reason. Your child's normal cystic fibrosis treatment will continue as usual.
How to find out more
Stephen McWilliam
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.